ERBB2 and breast carcinoma: Since we observed increased TIL infiltration following HER-2 DC1 vaccination and higher levels of PD-1 expression on TIL, we investigated whether combination with anti-HER2 antibodies, class II HER2-DC1 vaccine, and anti-PD-1 therapy have an impact on tumor burden in the TUBO breast cancer model.